Figure 3From: A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies Plasma HSP70 protein concentrations on days 1, 8 and 15 of Cycle 1 for 7–114 mg/m 2 and 150–259 mg/m 2 dose groups. Back to article page